Voyager Therapeutics (VYGR) Expected to Announce Earnings on Wednesday

Voyager Therapeutics (NASDAQ:VYGR) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $16.58 million for the quarter.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $4.22 on Monday. The company has a market cap of $230.54 million, a P/E ratio of 5.94 and a beta of 0.91. The stock’s 50-day moving average is $5.37 and its 200-day moving average is $6.10. Voyager Therapeutics has a 52-week low of $4.00 and a 52-week high of $10.66.

Insider Transactions at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 10,778 shares of company stock valued at $58,548. Company insiders own 4.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday, January 27th. Citigroup started coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $5.73 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $9.00 price objective (down previously from $11.00) on shares of Voyager Therapeutics in a research report on Tuesday, February 11th. Finally, StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $15.72.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.